A wide range of key stakeholders have started embracing and validating Real World Evidence (RWE) as a trusted source for healthcare decision making. Recently, regulatory bodies and payers have published new guidelines to formally incorporate RWE as part of their approval processes. And increasingly, patients are asking for evidence of treatment efficacy when participating in the development of new medicines.
These updated guidelines, coupled with increased patient interest and engagement, offer new opportunities for pharmaceutical companies to leverage RWE across all stages of the product lifecycle.
Attend our virtual conference and learn how to:
- Accelerate patient access to innovative treatments using RWE
- Identify collaboration opportunities and early dialog with regulators and payers to understand their evidence requirements
- Explore the increasingly large role Medical Affairs is playing in driving treatment development
- Optimize technology for more predictable outcomes of your evidence strategy
- Incorporate the patient voice as part of your long-term follow-up strategy to demonstrate impact of your treatment
Related Content
Improving Patient Outcomes: AI-Based Phenotyping for Diagnosis, Treatment, and Clinical Trials
Join a panel of OM1’s clinical experts in cardiometabolic disease, immunology, and mental health as they explore how Artificial Intelligence (AI) can find phenotypic patterns and unlock insights hidden in real-world data.
Bridging the Gap: Strategies for Patient-Centered Real-World Evidence in Rare Diseases
Watch this webinar exploring real challenges and solutions for generating patient-centered real-world evidence (RWE) in the context of rare diseases to support clinical development through commercial post-approval.
The role of patient-centric technologies & tokenization in RWE studies
Join the Castor team on the 3rd May 2023 with Aaron Berger from UBC & Ryan Moog from Datavant where we will dive deep into all things RWE, patient-centric technologies and the role of tokenization in clinical trials. You will hear about RWE case studies from the experts, learn new trends in the adoption of DCTs and how the role of patient-centric technologies & tokenization can contribute to successful RWE studies.